Your browser doesn't support javascript.
Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial.
Rashidi, Farid; Barco, Stefano; Rezaeifar, Parisa; Sadeghipour, Parham; Ghodrati, Samad; Bakhshandeh, Hooman; Mousavi-Aghdas, Seyed Ali; Sadeghi, Armin; Sharifi, Akbar; Valizadeh, Hamed; Mikaeili, Haleh; Rafiee, Farnaz; Navarbaf, Zahar; Farajian, Gita; Mahmoodpoor, Ata; Bikdeli, Behnood; Ansarin, Khalil.
  • Rashidi F; Tuberculosis and lung disease research center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: fr2652@yahoo.com.
  • Barco S; Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, Mainz, Germany; Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland.
  • Rezaeifar P; Tuberculosis and lung disease research center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Sadeghipour P; Cardiovascular Intervention Research Center, Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran; Clinical Trial Center, Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Ghodrati S; Department of Pulmonology, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Bakhshandeh H; Clinical Trial Center, Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran; Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Mousavi-Aghdas SA; Tuberculosis and lung disease research center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Sadeghi A; Tuberculosis and lung disease research center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Sharifi A; Tuberculosis and lung disease research center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Valizadeh H; Tuberculosis and lung disease research center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Mikaeili H; Tuberculosis and lung disease research center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Rafiee F; Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Navarbaf Z; Tuberculosis and lung disease research center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Farajian G; Department of Pulmonology, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Mahmoodpoor A; Department of Anesthesiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Bikdeli B; Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Yale Center for Outcomes Research and Evaluation (CORE), New Haven, CT, USA; Cardiovascular Research Foundation (CRF), New York, NY, USA.
  • Ansarin K; Tuberculosis and lung disease research center, Tabriz University of Medical Sciences, Tabriz, Iran.
Thromb Res ; 216: 125-128, 2022 08.
Article in English | MEDLINE | ID: covidwho-1559912
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tissue Plasminogen Activator / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Adult / Humans Language: English Journal: Thromb Res Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tissue Plasminogen Activator / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Adult / Humans Language: English Journal: Thromb Res Year: 2022 Document Type: Article